Literature DB >> 20025454

Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance.

Alexander M Ponizovsky1, Anatoly Margolis, Ludmila Heled, Paula Rosca, Irena Radomislensky, Alexander Grinshpoon.   

Abstract

AIM: A prospective longitudinal design was employed to examine the effects of buprenorphine maintenance on quality of life (QOL), clinical, and psychosocial characteristics of heroin-dependent patients.
METHOD: Between 2003 and 2005 data were collected on 259 patients attending the outpatient centers for treatment of drug addictions across Israel, of which 157 were reevaluated 16 weeks later and 105 reevaluated 32 weeks later using the Clinical Global Impression, Distress Scale for Adverse Symptoms, Quality of Life Enjoyment and Satisfaction Questionnaire, General Health Questionnaire, General Self-Efficacy Scale, and the Multidimensional Scale of Perceived Social Support. Univariate and multivariate analyses were conducted to examine the association between the parameters and the cross-sectional and longitudinal predictions of the QOL outcomes.
RESULTS: The groups did not differ in baseline values and their post-treatment ratings revealed significant improvement on virtually all the scales. Perceived self-efficacy and social support from friends and significant others at baseline as well as their changes over time were the best predictors of the QOL in the short and long terms. The study's limitations are noted.
CONCLUSIONS: The beneficial effects on the QOL were associated with improvement in the psychosocial parameters and a reduction in buprenorphine-related side effects and psychological distress. This study could stimulate research to compare the QOL related to buprenorphine and methadone treatment and serve as a basis on which a controlled study should be performed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20025454     DOI: 10.3109/10826080902873010

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  13 in total

Review 1.  Quality of life as an outcome of opioid use disorder treatment: A systematic review.

Authors:  Jeremy W Bray; Brandon Aden; Ashley A Eggman; Leah Hellerstein; Eve Wittenberg; Bohdan Nosyk; Judy C Stribling; Bruce R Schackman
Journal:  J Subst Abuse Treat       Date:  2017-02-10

2.  Trends in opioid analgesics consumption, Israel, 2000-2008.

Authors:  Alexander M Ponizovsky; Eli Marom; Alexander Zeldin; Nathan I Cherny
Journal:  Eur J Clin Pharmacol       Date:  2010-11-06       Impact factor: 2.953

3.  Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.

Authors:  P Todd Korthuis; Mary Jo Tozzi; Vijay Nandi; David A Fiellin; Linda Weiss; James E Egan; Michael Botsko; Angela Acosta; Marc N Gourevitch; David Hersh; Jeffrey Hsu; Joshua Boverman; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

4.  Buprenorphine disrupts sleep and decreases adenosine concentrations in sleep-regulating brain regions of Sprague Dawley rat.

Authors:  Elizabeth A Gauthier; Sarah E Guzick; Chad M Brummett; Helen A Baghdoyan; Ralph Lydic
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

5.  Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.

Authors:  Michael D Stein; Micah T Conti; Debra S Herman; Bradley J Anderson; Genie L Bailey; Donnell Van Noppen; Ana M Abrantes
Journal:  Am J Addict       Date:  2019-04-16

6.  Biographical data of patients in drug substitution programmes.

Authors:  Hans Tönies
Journal:  Wien Med Wochenschr       Date:  2012-01

7.  Design, Implementation, and Evolution of the Medicaid Outcomes Distributed Research Network (MODRN).

Authors:  Kara Zivin; Lindsay Allen; Andrew J Barnes; Stefanie Junker; Joo Yeon Kim; Lu Tang; Susan Kennedy; Katherine A Ahrens; Marguerite Burns; Sarah Clark; Evan Cole; Dushka Crane; David Idala; Paul Lanier; Shamis Mohamoud; Marian Jarlenski; Mary Joan McDuffie; Jeffery Talbert; Adam J Gordon; Julie M Donohue
Journal:  Med Care       Date:  2022-07-15       Impact factor: 3.178

8.  Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020.

Authors:  Bradley D Stein; Brendan Saloner; Rose Kerber; Mark Sorbero; Adam J Gordon
Journal:  Ann Emerg Med       Date:  2022-03-16       Impact factor: 6.762

9.  Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.

Authors:  Gerald Cochran; Julie Bruneau; Nicholas Cox; Adam J Gordon
Journal:  Subst Abus       Date:  2020       Impact factor: 3.716

10.  It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Authors:  Brendan Saloner; Barbara Andraka Christou; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2021-04-02       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.